Benjamin Larimer

Benjamin Larimer
Associate Professor

Scientist (C), UAB Immunology Institute , School of Medicine
Associate Scientist (C), O'Neal Comprehensive Cancer Center , School of Medicine
Associate Professor (P), Radiology , School of Medicine
Associate Scientist, Experimental Therapeutics , O'Neal Comprehensive Cancer Center
Associate Scientist (C), Center for Clinical and Translational Science (CCTS) , General Clinical Research Center

Selected Publications

Academic Article

Year	Title	Altmetric
2023	Imaging of Activated T Cells. Journal of Nuclear Medicine. 64:30-33. 2023
2022	¹⁸F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition. Clinical Cancer Research. 28:327-337. 2022
2021	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.. Nature Biomedical Engineering. 5:1246-1260. 2021
2021	[⁸⁹zr]-pertuzumab pet imaging reveals paclitaxel treatment efficacy is positively correlated with her2 expression in human breast cancer xenograft mouse models. Molecules. 26. 2021
2020	Imaging for Response Assessment in Cancer Clinical Trials. Seminars in Nuclear Medicine. 50:488-504. 2020

Principal Investigator On

Private Grant awarded by AVID RADIOPHARMACEUTICALS

Quantitative PET Imaging for Oncologic Immune Response Prediction awarded by National Cancer Institute/NIH/DHHS

Site-Specific Immune Cell Activation Detection for Improving Individualized Cancer Immunotherapy awarded by NIH - OFFICE OF THE DIRECTOR

Investigator On

Private Grant awarded by CYTOSITE BIOPHARMA INC

Private Grant awarded by CYTOSITE BIOPHARMA INC

Private Grant awarded by CURIUM US LLC

Education And Training

Doctor of Philosophy in Biochemistry, University of Missouri-Columbia 2014

Full Name

Benjamin Larimer